Top Markets
#1 EXOD EXOD +56.80%
#2 MowCat MowCat +48.16%
#3 Glidr Glidr +36.87%
#4 CoW Protocol CoW Protocol +36.53%
#5 RedStone RedStone +28.90%
#6 Humanity Humanity +26.35%
#7 Codatta Codatta +22.55%
#8 Walrus Walrus +19.98%
#9 The Black Bull The Black Bull +17.02%
#10 Enso Enso +16.70%
Coin of the day
EXOD EXOD
設定
言語
日本
通貨
USD
テーマ
Lysogene S.A. Lysogene S.A.

Lysogene S.A.

LYS
株式のランク #36618
Lysogene S.A. is a biopharmaceutical firm specializing in gene therapy,... Lysogene S.A. is a biopharmaceutical firm specializing in gene therapy, dedicated to discovering and advancing treatments for children affected by severe neurodegenerative lysosomal storage disorders. Its development pipeline includes LYS-SAF302, which is currently undergoing Phase II/III clinical trials for mucopolysaccharidosis type IIIA (MPS IIIA). Another promising candidate, LYS-GM101, is in Phase I/II development, targeting GM1 gangliosidosis. The company has also forged a research alliance with the Weizmann Institute of Science to pioneer novel adeno-associated virus (AAV) gene therapy approaches for conditions such as neuronopathic Gaucher disease, Parkinson's disease, and other related illnesses. Lysogene S.A. was established in 2009 and is headquartered in Neuilly-sur-Seine, France.
株価
$0.30221445
最終同期: 2023-05-22
時価総額
$2.49M
変化（1日）
-0.10%
変化（1年）
0.00%
国
FR
取引 Lysogene S.A. (LYS)

カテゴリー

Healthcare
Lysogene S.A.（LYS）のP/B比率
2026 時点のP/B比率 TTM: 0
Lysogene S.A. の最新の財務報告および株価によると、現在のP/B比率（TTM）は 0 です。2026 年末時点でのP/B比率は 0 でした。
Lysogene S.A. の P/B 比率の履歴（2026 ～ 2026）
各年末時点のP/B比率
年 P/B比率 変化
提供された日付のデータは十分ではありません。
同業他社のP/B比率
企業 P/B比率 P/B比率の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.4612 -
BE